Sinco Pharma
Sinco Pharma, a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a key provider of high-quality pharmaceutical products, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. With a commitment to innovation and quality, Sinco Pharma offers a diverse range of products, including generic medications and custom synthesis services, which are distinguished by their rigorous quality control and compliance with international standards. The company has achieved significant milestones, including certifications from major regulatory bodies, solidifying its market position as a trusted supplier in the global pharmaceutical landscape. Sinco Pharma continues to expand its reach, driven by a dedication to enhancing healthcare outcomes worldwide.
DitchCarbon Score
How does Sinco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinco Pharma's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinco Pharma's reported carbon emissions
In 2022, Sinco Pharma reported total carbon emissions of approximately 329,310 kg CO2e, with emissions distributed across various scopes. The breakdown includes about 93,260 kg CO2e from Scope 1 (mobile combustion), approximately 171,420 kg CO2e from Scope 2 (purchased electricity), and around 64,170 kg CO2e from Scope 3, which encompasses business travel, alongside 2,860 kg CO2e from waste generated in operations. Sinco Pharma's emissions data is cascaded from its parent company, Sinco Pharmaceuticals Holdings Limited, reflecting the company's commitment to transparency in its environmental impact. However, there are currently no specific reduction targets or climate pledges disclosed, indicating a potential area for future development in their sustainability strategy. Overall, while Sinco Pharma has made strides in reporting its emissions, the absence of defined reduction initiatives suggests an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 93,260 |
| Scope 2 | 171,420 |
| Scope 3 | 67,030 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinco Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
